Q-omics provides the consensus-scored URAD profile across patient tissues and cancer cell-line models. URAD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, URAD is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, URAD RNA expression shows 8,542 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where URAD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for URAD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes URAD survival associations across molecular data types. URAD RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible URAD RNA expression–survival associations across cancer types. High URAD expression shows unfavorable associations in LUAD, UCS, HNSC, OV, TGCT and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify LUAD as the clearest survival context for URAD RNA expression.
This table summarizes URAD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for URAD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. URAD shows lower tumor expression in KIRC, COAD, BRCA, STAD and READ. The KIRC box plot shows higher URAD RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p < 0.001).
This table shows molecular features associated with URAD in patient tissues and cancer cell lines. In patient samples, URAD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, URAD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
